ESMO 2019 | Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results

Name: Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results
Uploaded: 2019-09-29T00:00:00Z
Duration: 4 min 34 s
Description: Antonio González Martín, MD, Clínica Universidad de Navarra, Madrid, Spain, presents results from the Phase III PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016) of niraparib in newly diagnosed advanced ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Antonio González-Martín • 29 Sep 2019

ESMO 2019

Gynecological Cancer Ovarian Cancer

PRIMA

Antonio González Martín, MD, Clínica Universidad de Navarra, Madrid, Spain, presents results from the Phase III PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016) of niraparib in newly diagnosed advanced ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.